Edwards Lifesciences Q2 FY26: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 4, 2026
Revenue$1.74B
+14% year over year
Gross profit$1.35B
77% margin
Operating profit$0.51B
29% margin
Net profit$0.24B
14% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.74 | 100% | +14% |
| Aortic valve replacement | 1.26 | 72% | +11% |
| Surgical | 0.28 | 16% | |
| Transcatheter mitral | 0.20 | 12% | +48% |
| Cost of revenue | −0.39 | 23% | |
| Gross profit | 1.35 | 77% margin | |
| R&D | −0.28 | 16% | −2pp |
| SG&A | −0.56 | 32% | −1pp |
| Operating profit | 0.51 | 29% margin | +3pp |
| Tax | −0.27 | ||
| Net profit | 0.24 | 14% margin | −8pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest